JPH08501097A - 臨床診断及び治療用部分を含む生体適合性ポリマー - Google Patents
臨床診断及び治療用部分を含む生体適合性ポリマーInfo
- Publication number
- JPH08501097A JPH08501097A JP6507247A JP50724793A JPH08501097A JP H08501097 A JPH08501097 A JP H08501097A JP 6507247 A JP6507247 A JP 6507247A JP 50724793 A JP50724793 A JP 50724793A JP H08501097 A JPH08501097 A JP H08501097A
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- composition
- group
- acid
- linked
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/14—Peptides, e.g. proteins
- A61K49/146—Peptides, e.g. proteins the peptide being a polyamino acid, e.g. poly-lysine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/12—Macromolecular compounds
- A61K49/126—Linear polymers, e.g. dextran, inulin, PEG
- A61K49/128—Linear polymers, e.g. dextran, inulin, PEG comprising multiple complex or complex-forming groups, being either part of the linear polymeric backbone or being pending groups covalently linked to the linear polymeric backbone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/06—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules
- A61K51/065—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules conjugates with carriers being macromolecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/806—Electrical property or magnetic property
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/84—Manufacture, treatment, or detection of nanostructure
- Y10S977/895—Manufacture, treatment, or detection of nanostructure having step or means utilizing chemical property
- Y10S977/896—Chemical synthesis, e.g. chemical bonding or breaking
- Y10S977/898—Enzymatic
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/915—Therapeutic or pharmaceutical composition
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/927—Diagnostic contrast agent
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/927—Diagnostic contrast agent
- Y10S977/93—MRI contrast agent
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/24—Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1. 生体適合性の医用組成物であって、以下の組成からなることを特徴とす る。 ポリマー性担体、 上記ポリマー性担体に連結された保護鎖、及び、 上記担体、或いは上記担体及び上記保護鎖に連結されたリポーター基。 2. 請求項1に記載の組成物であって、以下の構造式を持つことを特徴とす る。 基はいかなる順序で連結されてもよく、ここで、kは100-560であり、 R1は(CH2)4NHCO(CH2)nCOOCH2CH2A−B−OR3で、ここ でn は2-6であり、 Aは、[OCH2CH2]xで、ここで、xは15-220であり、 Bは、[OCH2CH2]x、或いは[OCH(CH3)CH2]yで、ここ で、y+x は17-220であり、 R2は、キレート形成基で、又、 R3は、H,(CH2)yCH3,或いは(CH2)yCOOHで、yは0-7である。 3. 請求項1に記載の組成物であって、上記ポリマー性担体がポリアミノ酸 、ポリエチレンイミン、天然のサッカリド、アミノ化多糖、アミノ化オリゴ糖、 ポリアミドアミン、ポリアクリル酸、或いはポリアルコールの集団から選ばれる ことを特徴とする。 4. 請求項3に記載の組成物であって、上記ポリアミノ酸が20-560のアミノ 酸単位を持つことを特徴とする。 5. 請求項3に記載の組成物であって、上記ポリアミノ酸が単一種のアミノ 酸のポリマーであることを特徴とする。 6. 請求項3に記載の組成物であって、上記ポリアミノ酸が少なくとも2種 の異なったアミノ酸のポリマーであることを特徴とする。 7. 請求項3に記載の組成物であって、上記ポリアミノ酸がブロックコポリ マーであることを特徴とする。 8. 請求項3に記載の組成物であって、上記ポリアミノ酸が切断可能な結合 によって連結されたポリアミノ酸の断片からなることを特徴とする。 9. 請求項8に記載の組成物であって、上記の切断可能な結合がS-S結合であ ることを特徴とする。 10. 請求項3に記載の組成物であって、上記ポリアミノ酸がポリ−l−リジ ン、ポリ−d−リジン、ポリーα,β−(2−アミノエチル)−D,L−アスパ ラギン酸アミド、或いはポリ−l−アスパラギン酸であることを特徴とする。 11. 請求項3に記載の組成物であって、上記ポリアミノ酸が非タンパク質性 であることを特徴とする。 12. 請求項1に記載の組成物であって、上記保護鎖がポリエチレングリコー ル、メトキシポリエチレングリコール、メトキシポリプロピレングリコール、ポ リエチレングリコールやメトキシポリエチレングリコール或いはメトキシプロピ レングリコールのコポリマー、或いはそれらの誘導体であることを特徴とする。 13. 請求項1に記載の組成物であって、上記保護鎖がポリエチレングリコー ル、及びポリアミノ酸、多糖、ポリアミドアミン、ポリエチレンアミン或いはポ リヌクレオチドの集団からの1つとのブロック・コポリマーであることを特徴と する。 14. 請求項1に記載の組成物であって、上記保護鎖がジカルボン酸のモノエ ステルを含むポリエチレングリコールのコポリマーであることを特徴とする。 15. 請求項1に記載の組成物であって、上記保護鎖が500-10,000ダルトンの 分子量を持つことを特徴とする。 16. 請求項1に記載の組成物であって、上記リポーター基がキレート形成基 であることを特徴とする。 17. 請求項1に記載の組成物であって、上記リポーター基がピリジルジチオ アシル基、或いはジアゾ、又はヒドラゾ基であることを特徴とする。 18. 請求項17に記載の組成物であって、上記ピリジルジチオアシル基がN-( 2−ピリジルジチオ)プロピオニル基、N-ヒドロキシスクシンイミジル、N-ヒド ロキシスルホスクシンイミジル、イミダゾリル、ベンゾトリアゾリル、アミノア ルキル、アルデヒド、チオアルキル、チオラン、ハロゲン化アシル、ハロゲン化 アルキル、或いはハロゲン化フェニルであることを特徴とする。 19. 請求項18に記載の組成物であって、上記ジアゾ、或いはヒドラゾ基が、 4-ヒドラジノオキシエチル、4-ヒドラジノベンジル、ジアシリニル、アジドフェ ニル、或いはアジドアルキル基であることを特徴とする。 20. 請求項1に記載の組成物であって、上記リポーター基がふっ素含有分子 であることを特徴とする。 21. 請求項1に記載の組成物であって、上記リポーター基が造影剤を含むこ とを特徴とする。 22. 請求項21に記載の組成物であって、上記造影剤が常磁性あるいは超磁性 元素を含むことを特徴とする。 23. 請求項21に記載の組成物が、更に、上記キレート形成基に連結したα− 、β−、或いはγ一放射性核種からなることを特徴とする。 24. 請求項1に記載の組成物であって、上記リポーター基が治療薬を含むこ とを特徴とする。 25. 請求項24に記載の組成物であって、上記治療薬が細胞増殖抑制、抗生物 質、ホルモン、鎮痛、向精神、抗炎症、抗ウイルス、或いは抗真菌性の薬剤、或 いはリンホカインあることを特徴とする。 26. 請求項1に記載の組成物であって、更に、上記ポリマー性担体、保護鎖 、或いはその両者に連結された標的指向基を含むことを特徴とする。 27. 請求項26に記載の組成物であって、上記標的指向基が抗体、抗体の断片 、キメラ抗体、酵素、レクチン、或いはサッカリドリガンドであることを特徴と する。 28. 請求項1に記載の組成物であって、上記リポーター基がけい素、硫黄、 或いは炭素を含むポリマー、酸化けい素含有コロイド、又は、コロイド粒子或い は沈殿物であることを特徴とする。 29. 請求項28に記載の組成物であって、上記コロイド粒子が遷移元素、或い は原子番号21-29、42、44、又は57-71を持つランタニドの酸化物、硫化物、或い は水酸化物を含むことを特徴とする。 30. 請求項1に記載の組成物を調製する方法であって、上記ポリマー担体を 上記保護鎖に連結して保護された担体を生成し、及び、上記の保護された担体を 上記リポーター基に連結することをを特徴とする。 31. 請求項30に記載の方法であって、上記保護鎖がメトキシポリエチレング リコール類似体からなり、上記ポリマー性担体の上記類似体との連結が半安定性 ゲルを生成することを特徴とする。 32. 請求項30に記載の方法であって、更に、上記組成物の上記担体、保護鎖 、或いはその両者に標的指向基を連結することを特徴とする。 33. 請求項1に記載の組成物の疾病治療における利用であって、上記組成物 の治療的有効量を患者に投与し、上記リポーター基を検出して上記組成物の分布 の視覚化画像を得ることが出来る画像診断技法を用いて患者を精査することによ り利用することを特徴とする。 34. 請求項1に記載の組成物の疾病治療用医薬製造のための利用であって、 上記医薬の治療的有効量を患者に投与し、上記リポーター基を検出して上記医薬 の分布の視覚化画像を得ることが出来る画像診断技法を用いて患者を精査するこ とによる疾病治療の医薬の製造に利用することを特徴とする。 35. 請求項33或いは34に記載の組成物であって、上記投与が静脈内或いは腹 腔内注射によることを特徴とする。 36. 請求項33或いは34に記載の組成物であって、上記画像診断技法が磁気共 鳴画像診断、核医薬画像診断、陽電子放射断層撮影法、或いは単一光量子放射コ ンピューター断層撮影法であることを特徴とする。 37. 請求項33或いは34に記載の組成物であって、更に、上記患者の直径1ミ リメター以下の血管を精査して上記ミリメーター以下の血管の視覚化画像を得る ことからなることを特徴とする。 38. 請求項33或いは34に記載の組成物であって、上記リポーター基が患者の 体重1kg当り 0.05 mmol以下の用量で提供されるガドリニウムからなることを特 徴とする。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US94059092A | 1992-09-04 | 1992-09-04 | |
US07/940,590 | 1992-09-04 | ||
PCT/US1993/007880 WO1994005203A1 (en) | 1992-09-04 | 1993-08-23 | Biocompatible polymers containing diagnostic or therapeutic moieties |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2002216736A Division JP2003128579A (ja) | 1991-10-07 | 2002-07-25 | 特定種のlfa−3またはcd2結合蛋白質を投与することによる同種移植または異種移植の寛容性を改善するための方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH08501097A true JPH08501097A (ja) | 1996-02-06 |
Family
ID=25475106
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP6507247A Withdrawn JPH08501097A (ja) | 1992-09-04 | 1993-08-23 | 臨床診断及び治療用部分を含む生体適合性ポリマー |
Country Status (7)
Country | Link |
---|---|
US (1) | US5593658A (ja) |
EP (1) | EP0665729B1 (ja) |
JP (1) | JPH08501097A (ja) |
AU (1) | AU5085793A (ja) |
DE (1) | DE69332952T2 (ja) |
ES (1) | ES2199226T3 (ja) |
WO (1) | WO1994005203A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004105799A1 (ja) * | 2003-05-29 | 2004-12-09 | Toudai Tlo, Ltd. | 安定化高分子ミセル |
WO2006003731A1 (ja) * | 2004-07-05 | 2006-01-12 | Kanagawa Academy Of Science And Technology | 高分子ミセル型mri造影剤 |
JP2014058562A (ja) * | 2008-01-09 | 2014-04-03 | Pharmain Corp | 治療薬送達のための可溶性疎水性コア担体組成物、およびその製造・使用方法 |
Families Citing this family (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5707604A (en) * | 1986-11-18 | 1998-01-13 | Access Pharmaceuticals, Inc. | Vivo agents comprising metal-ion chelates with acidic saccharides and glycosaminoglycans, giving improved site-selective localization, uptake mechanism, sensitivity and kinetic-spatial profiles |
US5672334A (en) * | 1991-01-16 | 1997-09-30 | Access Pharmaceuticals, Inc. | Invivo agents comprising cationic metal chelators with acidic saccharides and glycosaminoglycans |
WO1994002068A1 (en) * | 1992-07-21 | 1994-02-03 | The General Hospital Corporation | System of drug delivery to the lymphatic tissues |
US5871710A (en) * | 1992-09-04 | 1999-02-16 | The General Hospital Corporation | Graft co-polymer adducts of platinum (II) compounds |
US5811076A (en) * | 1993-05-20 | 1998-09-22 | The Regents Of The University Of California | Macromolecular contrast media for MR imaging |
US5605672A (en) * | 1993-06-09 | 1997-02-25 | The General Hospital Corporation | Blood pool imaging composition and method of its use |
US5958372A (en) * | 1994-06-28 | 1999-09-28 | Nycomed Imaging As | Low viscosity chelating polymers for diagnostic imaging |
US6353055B1 (en) * | 1994-11-18 | 2002-03-05 | Supratek Pharma Inc. | Polynucleotide compositions |
US6221959B1 (en) | 1994-11-18 | 2001-04-24 | Supratek Pharma, Inc. | Polynucleotide compositions |
US6106866A (en) * | 1995-07-31 | 2000-08-22 | Access Pharmaceuticals, Inc. | In vivo agents comprising cationic drugs, peptides and metal chelators with acidic saccharides and glycosaminoglycans, giving improved site-selective localization, uptake mechanism, sensitivity and kinetic-spatial profiles, including tumor sites |
US5762909A (en) * | 1995-08-31 | 1998-06-09 | General Electric Company | Tumor targeting with polymeric molecules having extended conformation |
DE19548114C2 (de) * | 1995-12-21 | 2000-04-27 | Deutsches Krebsforsch | Konjugat, umfassend einen Wirkstoff, ein Polypeptid und einen Polyether |
GB9600272D0 (en) * | 1996-01-06 | 1996-03-06 | Univ Nottingham | Polymers |
GB2324534B (en) * | 1996-01-06 | 2000-05-10 | Danbiosyst Uk | Composition for delivery of nucleic acid to a cell |
US6441025B2 (en) * | 1996-03-12 | 2002-08-27 | Pg-Txl Company, L.P. | Water soluble paclitaxel derivatives |
US5888476A (en) * | 1996-11-13 | 1999-03-30 | Mallinckrodt Medical, Inc. | Magnetic resonance blood pool agents |
CN1246059A (zh) * | 1997-01-29 | 2000-03-01 | 奈科姆成像有限公司 | 聚合物 |
AU7972798A (en) * | 1997-06-18 | 1999-01-04 | Rutgers University | Application of 13c-13c,13c-15n, and 13c-13c-15n isotopically enriched proteins as tissue-directed image-enhancement reagents for magnetic resonance imaging |
US6210655B1 (en) * | 1997-06-18 | 2001-04-03 | University Of Medicine & Dentistry Of Nj | Site-specific 13C-enriched reagents for diagnostic medicine by magnetic resonance imaging |
WO1999002194A1 (en) * | 1997-07-11 | 1999-01-21 | Innerdyne, Inc. | Methods and systems for preparing and sealing radiation delivery structures |
US6275231B1 (en) | 1997-08-01 | 2001-08-14 | American Calcar Inc. | Centralized control and management system for automobiles |
US6919076B1 (en) | 1998-01-20 | 2005-07-19 | Pericor Science, Inc. | Conjugates of agents and transglutaminase substrate linking molecules |
AU3870099A (en) * | 1998-04-28 | 1999-11-16 | Jagotec Ag | Hyaluronan-based imaging agents |
US6083486A (en) * | 1998-05-14 | 2000-07-04 | The General Hospital Corporation | Intramolecularly-quenched near infrared fluorescent probes |
US6592847B1 (en) * | 1998-05-14 | 2003-07-15 | The General Hospital Corporation | Intramolecularly-quenched near infrared flourescent probes |
US6333051B1 (en) | 1998-09-03 | 2001-12-25 | Supratek Pharma, Inc. | Nanogel networks and biological agent compositions thereof |
US6696089B2 (en) * | 1998-09-03 | 2004-02-24 | Board Of Regents Of The University Of Nebraska | Nanogel networks including polyion polymer fragments and biological agent compositions thereof |
FR2797769B1 (fr) * | 1999-09-01 | 2003-07-25 | Cis Bio Int | Produits radiopharmaceutiques et leur procede de preparation |
US7383076B2 (en) * | 2000-11-27 | 2008-06-03 | The General Hospital Corporation | Fluorescence-mediated molecular tomography |
US20030044353A1 (en) * | 2001-01-05 | 2003-03-06 | Ralph Weissleder | Activatable imaging probes |
EP1420688A4 (en) * | 2001-06-25 | 2005-08-31 | Us Gov Health & Human Serv | MACROMOLECULAR IMAGING AGENTS FOR LIVER VISUALIZATION |
AU2003207438A1 (en) * | 2002-01-02 | 2003-07-24 | Visen Medical, Inc. | Amine functionalized superparamagnetic nanoparticles for the synthesis of bioconjugates and uses therefor |
US20030147958A1 (en) * | 2002-01-29 | 2003-08-07 | Cheol-Hee Ahn | Biodegradable multi-block copolymers of poly(amino acid)s and poly(ethylene glycol) for the delivery of bioactive agents |
US7635463B2 (en) | 2002-02-27 | 2009-12-22 | Pharmain Corporation | Compositions for delivery of therapeutics and other materials |
AU2003219922B2 (en) * | 2002-02-27 | 2009-09-10 | Pharmain Corporation | Compositions for delivery of therapeutics and other materials, and methods of making and using the same |
US20050260259A1 (en) * | 2004-04-23 | 2005-11-24 | Bolotin Elijah M | Compositions for treatment with glucagon-like peptide, and methods of making and using the same |
EP1485716A1 (en) * | 2002-03-11 | 2004-12-15 | Visen Medical, Inc. | Optical imaging probes |
WO2003101495A1 (en) * | 2002-05-29 | 2003-12-11 | Immunomedics, Inc. | Methods and compositions for radioimmunotherapy of brain and cns tumors |
AU2003267540A1 (en) * | 2002-08-13 | 2004-02-25 | Sirus Pharmaceuticals Ltd | Biodegradable polymer |
WO2004108902A2 (en) * | 2003-06-04 | 2004-12-16 | Visen Medical, Inc. | Biocompatible fluorescent silicon nanoparticles |
DE10325752A1 (de) * | 2003-06-06 | 2004-12-30 | Faustus Forschungs Cie. Translational Cancer Research Gmbh | Lektin-Konjugate |
SG113562A1 (en) * | 2004-01-12 | 2005-08-29 | Agency Science Tech & Res | Polyalkyleneimine-graft-biodegradable polymers for delivery of bioactive agents |
EP2325642A1 (en) * | 2004-04-20 | 2011-05-25 | Emory University | Use of multimodality nanostructures to detect target substances |
BRPI0606395A2 (pt) * | 2005-01-05 | 2009-06-23 | Univ Texas | conjugados para ambas imagem e radioquimioterapia: composição, fabricação e aplicações |
WO2007028163A1 (en) * | 2005-09-02 | 2007-03-08 | Visen Medical, Inc. | Biocompatible fluorescent imaging agents |
WO2007028037A1 (en) * | 2005-09-02 | 2007-03-08 | Visen Medical, Inc. | Biocompatible n, n-disubstituted sulfonamide-containing fluorescent dye labels |
US8173819B2 (en) | 2005-09-02 | 2012-05-08 | Visen Medical, Inc. | Nicotinic and picolinic acid derived near-infrared fluorophores |
JP2009520040A (ja) * | 2005-12-19 | 2009-05-21 | ファーマイン コーポレーション | 治療薬の送達のための疎水性コアの担体組成物、及び同担体組成物の作製法及び使用法 |
US20070148094A1 (en) * | 2005-12-22 | 2007-06-28 | Uzgiris Egidijus E | Polymeric imaging agents and medical imaging methods |
EP1973575B1 (en) | 2005-12-22 | 2019-07-24 | Visen Medical, Inc. | Biocompatible fluorescent metal oxide nanoparticles |
ES2670852T3 (es) | 2007-02-09 | 2018-06-01 | Visen Medical, Inc. | Colorantes con policiclo y uso de los mismos |
WO2008109832A2 (en) * | 2007-03-08 | 2008-09-12 | Visen Medical, Inc. | Viable near-infrared fluorochrome labeled cells and methods of making and using same |
AU2008268262C1 (en) | 2007-06-26 | 2015-02-19 | Children's Medical Center Corporation | MetAP-2 inhibitor polymersomes for therapeutic administration |
US7960336B2 (en) | 2007-08-03 | 2011-06-14 | Pharmain Corporation | Composition for long-acting peptide analogs |
US8563527B2 (en) | 2007-08-20 | 2013-10-22 | Pharmain Corporation | Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same |
EP2732826B1 (en) | 2008-01-18 | 2017-11-08 | Visen Medical, Inc. | Fluorescent imaging agents |
US20110044968A1 (en) * | 2008-03-10 | 2011-02-24 | Pharmal N Corporation | Compositions for treatment with metallopeptidases, methods of making and using the same |
WO2009154963A1 (en) * | 2008-05-27 | 2009-12-23 | Board Of Regents, The University Of Texas System | Composition for therapy and imaging of cancer and associated methods |
US8864821B2 (en) * | 2008-11-26 | 2014-10-21 | Visen Medical, Inc. | Methods and compositions for identifying subjects at risk of developing stent thrombosis |
US9155471B2 (en) * | 2009-05-27 | 2015-10-13 | Lumicell, Inc'. | Methods and systems for spatially identifying abnormal cells |
US20110021908A1 (en) * | 2009-05-27 | 2011-01-27 | Lumicell Diagnostics, Inc. | Methods and systems for spatially identifying abnormal cells |
US9314304B2 (en) | 2010-12-08 | 2016-04-19 | Lumicell, Inc. | Methods and system for image guided cell ablation with microscopic resolution |
GB201106742D0 (en) * | 2011-04-20 | 2011-06-01 | Spheritech Ltd | Cross-linked poly-e-lysine |
JP6122840B2 (ja) | 2011-05-09 | 2017-04-26 | ビセン メディカル, インコーポレイテッド | 炭酸脱水酵素標的化剤およびそれの使用方法 |
US9375493B2 (en) | 2012-03-30 | 2016-06-28 | Visen Medical, Inc. | Bacterial imaging agents and methods of using same |
JP6370785B2 (ja) | 2012-08-15 | 2018-08-08 | ビセン メディカル, インコーポレイテッド | 前立腺がんイメージングのための前立腺特異的抗原薬剤およびその使用方法 |
KR20160037834A (ko) | 2013-03-14 | 2016-04-06 | 루미셀, 아이엔씨. | 의료 이미징 장치 및 사용 방법 |
JP6606487B2 (ja) | 2013-03-15 | 2019-11-13 | ビセン メディカル, インコーポレイテッド | invitroおよびinvivoイメージングおよび検出のための置換シラキサンテニウム赤色〜近赤外蛍光色素 |
WO2014144702A2 (en) | 2013-03-15 | 2014-09-18 | Visen Medical, Inc. | 4,4-disubstituted cyclohexyl bridged heptamethine cyanine dyes and uses thereof |
EP3016688B1 (en) * | 2013-07-01 | 2018-04-25 | The Australian National University | Radiolabelled material |
EP3492512A4 (en) | 2016-07-30 | 2020-04-08 | Nippon Kayaku Kabushiki Kaisha | NEW POLYMER DERIVATIVES, AND NEW POLYMER DERIVATIVE IMAGING PROBE USING SAID NEW POLYMER DERIVATIVES |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4647447A (en) * | 1981-07-24 | 1987-03-03 | Schering Aktiengesellschaft | Diagnostic media |
US4849208A (en) * | 1984-01-30 | 1989-07-18 | Enzo Biochem, Inc. | Detectable molecules, method of preparation and use |
US5069216A (en) * | 1986-07-03 | 1991-12-03 | Advanced Magnetics Inc. | Silanized biodegradable super paramagnetic metal oxides as contrast agents for imaging the gastrointestinal tract |
US5141739A (en) * | 1986-07-03 | 1992-08-25 | Advanced Magnetics, Inc. | Delivery of x-ray contrast agents using receptor mediated endocytosis |
DE3709851A1 (de) * | 1987-03-24 | 1988-10-06 | Silica Gel Gmbh Adsorptions Te | Nmr-diagnostische fluessigkeitszusammensetzungen |
GB8801646D0 (en) * | 1988-01-26 | 1988-02-24 | Nycomed As | Chemical compounds |
DE3806795A1 (de) * | 1988-02-29 | 1989-09-07 | Schering Ag | Polymer-gebundene komplexbildner, deren komplexe und konjugate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel |
US5213788A (en) * | 1988-09-29 | 1993-05-25 | Ranney David F | Physically and chemically stabilized polyatomic clusters for magnetic resonance image and spectral enhancement |
US5171563A (en) * | 1988-09-30 | 1992-12-15 | Neorx Corporation | Cleavable linkers for the reduction of non-target organ retention of immunoconjugates |
JP2517760B2 (ja) * | 1989-05-11 | 1996-07-24 | 新技術事業団 | 水溶性高分子化医薬製剤 |
US5094848A (en) * | 1989-06-30 | 1992-03-10 | Neorx Corporation | Cleavable diphosphate and amidated diphosphate linkers |
ATE153860T1 (de) * | 1990-04-10 | 1997-06-15 | Imarx Pharmaceutical Corp | Polymere und ihre verwendung als kontrastmittel bei der bilderzeugung mit magnetischer resonanz |
DE59103985D1 (en) * | 1990-05-30 | 1995-02-02 | Deutsches Krebsforsch | Polyethersubstituierte tumormittel. |
WO1992000748A1 (en) * | 1990-07-06 | 1992-01-23 | Enzon, Inc. | Poly(alkylene oxide) amino acid copolymers and drug carriers and charged copolymers based thereon |
JPH08502300A (ja) * | 1992-10-14 | 1996-03-12 | スターリング ウィンスロップ アイエヌシー. | 治療および診断像形成組成物および方法 |
US5811076A (en) * | 1993-05-20 | 1998-09-22 | The Regents Of The University Of California | Macromolecular contrast media for MR imaging |
US5605672A (en) * | 1993-06-09 | 1997-02-25 | The General Hospital Corporation | Blood pool imaging composition and method of its use |
-
1993
- 1993-08-23 EP EP94908874A patent/EP0665729B1/en not_active Expired - Lifetime
- 1993-08-23 DE DE69332952T patent/DE69332952T2/de not_active Expired - Lifetime
- 1993-08-23 ES ES94908874T patent/ES2199226T3/es not_active Expired - Lifetime
- 1993-08-23 AU AU50857/93A patent/AU5085793A/en not_active Abandoned
- 1993-08-23 WO PCT/US1993/007880 patent/WO1994005203A1/en active IP Right Grant
- 1993-08-23 JP JP6507247A patent/JPH08501097A/ja not_active Withdrawn
-
1994
- 1994-05-27 US US08/250,635 patent/US5593658A/en not_active Expired - Lifetime
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004105799A1 (ja) * | 2003-05-29 | 2004-12-09 | Toudai Tlo, Ltd. | 安定化高分子ミセル |
JPWO2004105799A1 (ja) * | 2003-05-29 | 2006-07-20 | 株式会社東京大学Tlo | 安定化高分子ミセル |
WO2006003731A1 (ja) * | 2004-07-05 | 2006-01-12 | Kanagawa Academy Of Science And Technology | 高分子ミセル型mri造影剤 |
JPWO2006003731A1 (ja) * | 2004-07-05 | 2008-04-17 | 財団法人神奈川科学技術アカデミー | 高分子ミセル型mri造影剤 |
JP4758346B2 (ja) * | 2004-07-05 | 2011-08-24 | 財団法人神奈川科学技術アカデミー | 高分子ミセル型mri造影剤 |
JP2014058562A (ja) * | 2008-01-09 | 2014-04-03 | Pharmain Corp | 治療薬送達のための可溶性疎水性コア担体組成物、およびその製造・使用方法 |
Also Published As
Publication number | Publication date |
---|---|
DE69332952T2 (de) | 2004-02-19 |
EP0665729B1 (en) | 2003-05-07 |
ES2199226T3 (es) | 2004-02-16 |
EP0665729A1 (en) | 1995-08-09 |
DE69332952D1 (de) | 2003-06-12 |
WO1994005203A1 (en) | 1994-03-17 |
EP0665729A4 (en) | 1995-11-29 |
US5593658A (en) | 1997-01-14 |
AU5085793A (en) | 1994-03-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH08501097A (ja) | 臨床診断及び治療用部分を含む生体適合性ポリマー | |
US5871710A (en) | Graft co-polymer adducts of platinum (II) compounds | |
EP0247156B1 (en) | Polychelating agents for image and spectral enhancement (and spectral shift) | |
US5756069A (en) | Amphipathic polychelating compounds and method of use | |
US5514379A (en) | Hydrogel compositions and methods of use | |
Rebizak et al. | Polymeric conjugates of Gd3+− diethylenetriaminepentaacetic acid and dextran. 1. Synthesis, characterization, and paramagnetic properties | |
EP0726781B1 (en) | In vivo agents comprising radioactive metal-ion chelates with acidic saccharides and glycosaminoglycans, giving improved site-selective localization, uptake mechanism, sensitivity and kinetic-spatial profiles | |
Bogdanov Jr et al. | Long-circulating blood pool imaging agents | |
US5336762A (en) | Polychelating agents for image and spectral enhancement (and spectral shift) | |
Krause et al. | Dendrimers in diagnostics | |
JP2894879B2 (ja) | 診断用造影剤 | |
US20110142762A1 (en) | Conjugates for medical imaging comprising carrier, targeting moiety and a contrast agent | |
WO2017126939A1 (ko) | 생체적합성 나노입자 및 이의 용도 | |
JPH06506230A (ja) | インターナリゼーションを用いた、x線コントラスト剤のデリバリー | |
WO1994002068A1 (en) | System of drug delivery to the lymphatic tissues | |
IE74852B1 (en) | Chelants | |
US5707604A (en) | Vivo agents comprising metal-ion chelates with acidic saccharides and glycosaminoglycans, giving improved site-selective localization, uptake mechanism, sensitivity and kinetic-spatial profiles | |
JPH09510239A (ja) | ポリキレート化剤 | |
US6638508B2 (en) | Modified avidin-type molecules as targeting agents for the liver and cells of the reticuloendothelial system | |
JP2000502109A (ja) | 作用物質、ポリペプチドおよびポリエーテルを含有してなるコンジュゲート | |
Rebizak et al. | Macromolecular contrast agents for magnetic resonance imaging: Influence of polymer content in ligand on the paramagnetic properties | |
JP2001509796A (ja) | 重合体 | |
WO1996000079A1 (en) | Graft co-polymer adducts of platinum (ii) compounds | |
US20040022733A1 (en) | Conjugated lysine copolymers | |
US20040022857A1 (en) | Synthesis of highly conjugated polymers |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20031105 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20040302 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040630 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20040531 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20040604 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20041104 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20041118 |
|
A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20050630 |